New triplet therapy targets Hard-to-Treat bladder cancer in small trial
NCT ID NCT05335941
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 17 times
Summary
This study tests a combination of three drugs (pemetrexed, etrumadenant, and zimberelimab) in 10 adults with advanced bladder cancer that has a specific genetic change called MTAP deficiency. All participants had already received immunotherapy. The goal is to see if the triplet therapy can shrink tumors or control the disease, while monitoring side effects. The trial is only at MD Anderson Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.